Wells Fargo’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Wells Fargo’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-18,300	Closed	-$1.96M	–	7749
2023 Q1	$1.96M	Buy	18,300 +16,876	+1,185%	+$1.94M	﹤0.01%	2877
2022 Q4	$157K	Sell	1,424 -5,605	-80%	-$363K	﹤0.01%	4306
2022 Q3	$414K	Buy	7,029 +4,225	+151%	+$193K	﹤0.01%	3817
2022 Q2	$79K	Sell	2,804 -5,800	-67%	-$168K	﹤0.01%	4782
2022 Q1	$325K	Sell	8,604 -11,928	-58%	-$471K	﹤0.01%	4703
2021 Q4	$812K	Buy	20,532 +5,086	+33%	+$159K	﹤0.01%	4290
2021 Q3	$367K	Buy	15,446 +15,373	+21,059%	+$363K	﹤0.01%	4841
2021 Q2	$2K	Buy	+73	New	+$1.63K	﹤0.01%	6584

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Wells Fargo's RXDX Position: Q2 2023 in Review

Wells Fargo sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 18,300 shares — an estimated $1.96M sold.

Wells Fargo first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $1.96M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Wells Fargo reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Wells Fargo sold 18,300 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.96M.
Wells Fargo first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Wells Fargo's Prometheus Biosciences, Inc. Common Stock position peaked at $1.96M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.